The SomnaGraft-9 is a transdermal neuro-sedation patch measuring 4cm x 6cm, designed for use in procedural sedation, acute psychiatric crisis intervention, and pain management during field surgery. The patch employs a tri-layer delivery architecture: an outer hydrogel adhesive layer bonds to skin within 3 seconds regardless of moisture conditions; a middle microencapsulation layer holds a proprietary cocktail of GABA-potentiating compounds, synthetic endorphin analogs, and a Lazarus-patented molecule designated LP-9 (colloquially 'Lazarine'); and an inner iontophoretic layer uses a micro-battery to drive the compounds across the dermal barrier at a controlled, dose-regulated rate over a 6-hour window. LP-9 specifically targets the thalamo-cortical relay without suppressing brainstem autonomic function, producing deep sedation while preserving respiratory drive — a critical advance over earlier sedative patches that caused dangerous respiratory depression.

The SomnaGraft-9 incorporates a passive NFC chip that logs application time, estimated dose remaining, and skin conductance data to compatible medical devices. In licensed clinical settings, this data streams to patient management systems. The patch also features a tamper-evident color ring that turns grey if the patch has been removed and reapplied — a security measure introduced after widespread reports of patch harvesting, in which individuals would remove partially-used patches from sedated patients to extract residual LP-9 for recreational use.

Medically, the SomnaGraft-9 has become the preferred sedation method for augmentation surgeries performed outside licensed hospital settings — a booming market in GLMZ where unlicensed 'chop shops' perform neural implant work for lower-tier citizens who cannot afford licensed clinics. The patch's safety profile makes it attractive to operators who lack anesthesiologists, but the same accessibility has made it a primary vector for non-consensual sedation crimes.